Axsome Therapeutics (NASDAQ: AXSM) is preparing to release its financial results for the fourth quarter of 2025 before the market opens on February 23, 2026. Analysts anticipate the company will report an earnings loss of $0.72 per share alongside projected revenues of $191.33 million for the quarter. Investors can access details of the earnings call scheduled for 8:00 AM ET on the same day.
Performance metrics indicate that Axsome Therapeutics shares opened at $183.72 on Friday. Over the past year, the stock has fluctuated significantly, reaching a low of $86.99 and a high of $191.50. The company’s financial ratios reveal a debt-to-equity ratio of 1.66, a quick ratio of 1.50, and a current ratio of 1.57. Additionally, Axsome boasts a market capitalization of $9.26 billion, with a price-to-earnings ratio of -39.34 and a beta of 0.40.
Analyst Ratings and Price Targets
Several equity analysts have recently reassessed their ratings for Axsome Therapeutics. Needham & Company LLC maintained a “buy” rating and set a price target of $225.00 in a report released on January 5. Following suit, HC Wainwright raised its target from $200.00 to $260.00, also issuing a “buy” rating on January 20. Meanwhile, UBS Group increased its price target from $163.00 to $248.00 on January 6.
Conversely, Morgan Stanley downgraded the stock from “overweight” to “reduce” on January 8. Robert W. Baird also set a price objective of $209.00 in a research note dated January 13. Currently, data from MarketBeat.com shows that 16 analysts rate the stock as a “buy,” while two have issued a “sell” rating, resulting in an average rating of “Moderate Buy” and an average target price of $216.07.
Insider Transactions and Institutional Activity
Recent insider trading activity has raised eyebrows among investors. Chief Financial Officer Nick Pizzie sold 12,000 shares on January 22 at an average price of $187.92, generating a total of $2.26 million. Following this transaction, Pizzie retains 42,588 shares worth approximately $8.00 million. This sale accounted for a 21.98% decline in his ownership.
Additionally, Director Mark E. Saad sold 37,577 shares on December 31 for about $6.21 million, resulting in a significant 78.98% reduction in his stake in the company. Over the past three months, insiders have sold a total of 308,874 shares, valued at over $51.39 million, with insiders holding 22.30% of the stock.
Institutional investors appear to be actively engaging with Axsome Therapeutics. In the fourth quarter, Kemnay Advisory Services Inc. acquired a new stake valued at approximately $31,000. Other notable purchases include Ameriflex Group Inc. and Advisory Services Network LLC, each taking new positions valued at $37,000 and $40,000, respectively. Currently, institutional investors own 81.49% of Axsome’s stock.
About Axsome Therapeutics
Axsome Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting central nervous system (CNS) disorders. The firm focuses on small-molecule drugs aimed at addressing unmet medical needs, particularly in areas such as depression, migraine, narcolepsy, and fibromyalgia. Employing a precision medicine approach, Axsome leverages pharmacologic innovations to target disease mechanisms and enhance patient outcomes. The company’s pipeline includes several late-stage and approved product candidates, positioning it as a key player in the biopharmaceutical sector.
